.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,217,347

« Back to Dashboard

Claims for Patent: 4,217,347

Title: Method of treating hypertension and medicaments therefor
Abstract:A method for reducing blood pressure comprises administering a combination of a diuretic compound and a compound having the general formula ##STR1##
Inventor(s): Horovitz; Zola P. (Princeton, NJ), Rubin; Bernard (Lawrence Township, Cumberland County, NJ)
Assignee: E. R. Squibb & Sons, Inc. (Princeton, NJ)
Application Number:05/958,062
Patent Claims: 1. A method for reducing blood pressure which comprises orally administering to a mammalian species having elevated blood pressure a daily dosage of a combination comprising about 30 to 600 mg. of a compound having the formula ##STR3## wherein: R is hydroxy, lower alkoxy or NH.sub.2 ;

R.sub.1 and R.sub.4 each is hydrogen, lower alkyl or phenyl-lower alkyl;

R.sub.2 is hydrogen or R.sub.5 -CO;

R.sub.3 is hydrogen, hydroxy or lower alkyl;

R.sub.5 is lower alkyl, phenyl or phenyl-lower alkyl; and

n is 0, 1 or 2

and about 15 to 300 mg. of a diuretic selected from the group consisting of chlorothiazide, hydrochlorothiazide, flumethiazide, amiloride, hydroflumethiazide, bendroflumethiazide, methyclothiazide, trichlormethiazide, polythiazide, benzthiazide, ethacrynic acid, ticrynafen, chlorthalidone, furosemide, bumetanide, triamterene and spironolactone or salts of said compounds.

2. A method as in claim 1 wherein the combination comprises about 30 to 300 mg. of the compound of the formula and about 15 to 200 mg. of the diuretic.

3. A method as in claim 1 wherein the compound of the formula has R as hydroxy or lower alkoxy; R.sub.1 as hydrogen or lower alkyl; R.sub.2 as hydrogen or lower alkanoyl; R.sub.3 as hydrogen or hydroxy; R.sub.4 as hydrogen or lower alkyl; and n as 0 or 1.

4. A method as in claim 1 wherein the compound of the formula has R as hydroxy; R.sub.1 as hydrogen or methyl; R.sub.2 as hydrogen or acetyl; R.sub.3 as hydrogen; R.sub.4 as hydrogen or methyl; and n as 0 or 1.

5. A method as in claim 1 wherein the diuretic is chlorothiazide, hydrochlorothiazide, furosemide, ticrynafen or triameterene.

6. A method as in claim 1 wherein the diuretic is hydrochlorothiazide or furosemide.

7. A method as in claim 1 wherein the compound of the formula has R as hydrogen or lower alkoxy; R.sub.1 as hydrogen or lower alkyl; R.sub.2 as hydrogen or lower alkanoyl; R.sub.3 as hydrogen or hydroxy; R.sub.4 as hydrogen or lower alkyl; and n as 0 or 1; and the diuretic is chlorothiazide, hydrochlorothiazide, furosemide, ticrynafen or triamterene.

8. A method as in claim 1 comprising about 30 to 300 mg. of a compound of the formula wherein R is hydroxy or lower alkoxy; R.sub.1 and R.sub.4 each is hydrogen or lower alkyl; R.sub.2 is hydrogen or lower alkanoyl, R.sub.3 is hydrogen or hydroxy; and n is 0 or 1, and about 15 to 200 mg. of chlorothiazide, hydrochlorothiazide, furosemide, ticrynafen or triamterene.

9. A method as in claim 1 wherein the compound of the formula is (D-3-mercapto-2-methylpropanoyl)-L-proline and the diuretic is hydrochlorothiazide or furosemide.

10. A method as in claim 1 wherein the compound of the formula is (D-3-mercapto-2-methylpropanoyl)-L-proline in an amount of about 30 to 300 mg. and the diuretic is hydrochlorothiazide in an amount of about 15 to 200 mg.

11. A method as in claim 1 wherein the compound of the formula is (D-3-mercapto-2-methylpropanoyl)-L-proline in an amount of about 30 to 300 mg. and the diuretic is furosemide in an amount of about 15 to 200 mg.

12. An oral antihypertensive composition comprising about 30 to 600 mg. of a compound of the formula ##STR4## wherein: R is hydroxy, lower alkoxy or NH.sub.2 ;

R.sub.1 and R.sub.4 each is hydrogen, lower alkyl or phenyl-lower alkyl;

R.sub.2 is hydrogen or R.sub.5 -CO;

R.sub.3 is hydrogen, hydroxy or lower alkyl;

R.sub.5 is lower alkyl, phenyl or phenyl-lower alkyl;

n is 0, 1 or 2,

about 15 to 300 mg. of a diuretic selected from the group consisting of chlorothiazide, hydrochlorothiazide, amiloride, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylclothiazide, trichlormethiazide, polythiazide, benzthiazide, ethacrynic acid, ticrynafen, chlorthalidone, furosemide, bumetanide, triamterene, spironolactone and salts thereof, and a physiologically acceptable carrier therefor.

13. A composition as in claim 12 comprising about 30 to 300 mg. of the compound of the formula and about 15 to 200 mg. of the diuretic.

14. A composition as in claim 12 wherein the compound of the formula has R as hydroxy or lower alkoxy; R.sub.1 as hydrogen or lower alkyl; R.sub.2 as hydrogen or lower alkanoyl; R.sub.3 as hydrogen or hydroxy; R.sub.4 as hydrogen or lower alkyl; and n as 0 or 1.

15. A composition as in claim 12 wherein the compound of the formula has R as hydroxy; R.sub.1 as hydrogen or methyl; R.sub.2 as hydrogen or acetyl; R.sub.3 as hydrogen; R.sub.4 as hydrogen or methyl; and n as 0 or 1.

16. A composition as in claim 12 wherein the diuretic is chlorothiazide, hydrochlorothiazide, furosemide, ticrynafen or triamterene.

17. A composition as in claim 12 wherein the diuretic is hydrochlorothiazide or furosemide.

18. A composition as in claim 12 wherein the compound of the formula has R as hydrogen or lower alkoxy; R.sub.1 as hydrogen or lower alkyl; R.sub.2 as hydrogen or lower alkanoyl; R.sub.3 as hydrogen or hydroxy; R.sub.4 as hydrogen or lower alkyl; and n as 0 or 1; and the diuretic is chlorothiazide, hydrochlorothiazide, furosemide, ticrynafen or triamterene.

19. A composition as in claim 12 wherein the compound of the formula is (D-3-mercapto-2-methyl-propanoyl)-L-proline and the diuretic is hydrochlorothiazide or furosemide.

20. A composition as in claim 12 comprising about 30 to 300 mg. of (D-3-mercapto-2-methylpropanoyl)-L-proline and about 15 to 200 mg. of hydrochlorothiazide.

21. A composition as in claim 13 comprising about 30 to 300 mg. of (D-3-mercapto-2-methylpropanoyl)-L-proline and about 15 to 200 mg. of furosemide.

22. A composition as in claim 25 comprising about 5 to 125 mg. of (D-3-mercapto-2-methylpropanoyl)-L-proline and about 2.5 to 50 mg. of hydrochlorothiazide.

23. A composition as in claim 25 comprising about 5 to 125 mg. of (D-3-mercapto-2-methylpropanoyl)-L-proline and about 2.5 to 50 mg. of furosemide.

24. An oral hypertensive composition comprising about 5 to 125 mg. of (D-3-mercapto-2-methylpropanoyl)-L-proline and about 5 to 75 mg. of triamterene.

25. An oral antihypertensive composition comprising about 5 to 125 mg. of a compound of the formula ##STR5## wherein: R is hydroxy, lower alkoxy or NH.sub.2 ;

R.sub.1 and R.sub.4 each is hydrogen, lower alkyl or phenyl-lower alkyl;

R.sub.2 is hydrogen or R.sub.5 -CO;

R.sub.3 is hydrogen, hydroxy or lower alkyl;

R.sub.5 is lower alkyl, phenyl or phenyl-lower alkyl; and

n is 0, 1 or 2, about 2.5 to 50 mg. of a diuretic selected from the group consisting of chlorothiazide, hydrochlorothiazide, amiloride, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylclothiazide, trichlormethiazide, polythiazide, benzthiazide, ethacrynic acid, ticrynafen, chlorthalidone, furosemide, bumetanide, triamterene, spironolactone and salts thereof, and a physiologically acceptable carrier therefor.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc